Travere Therapeutics (TVTX) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $1.6 million.
- Travere Therapeutics' Cost of Revenue fell 252.15% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 597.64%. This contributed to the annual value of $7.7 million for FY2024, which is 3236.68% down from last year.
- Per Travere Therapeutics' latest filing, its Cost of Revenue stood at $1.6 million for Q3 2025, which was down 252.15% from $1.5 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Cost of Revenue registered a high of $4.7 million during Q1 2025, and its lowest value of -$1.1 million during Q4 2021.
- In the last 5 years, Travere Therapeutics' Cost of Revenue had a median value of $1.6 million in 2024 and averaged $1.9 million.
- As far as peak fluctuations go, Travere Therapeutics' Cost of Revenue crashed by 15164.09% in 2021, and later soared by 42580.65% in 2023.
- Travere Therapeutics' Cost of Revenue (Quarter) stood at -$1.1 million in 2021, then surged by 181.12% to $868000.0 in 2022, then skyrocketed by 425.81% to $4.6 million in 2023, then plummeted by 44.06% to $2.6 million in 2024, then crashed by 37.92% to $1.6 million in 2025.
- Its Cost of Revenue stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and $4.7 million for Q1 2025.